claim: lilly provides comprehensive update on progress of sars-cov-2 neutralizing antibody programs
evidence_1: lilly has successfully completed a phase 1 study (nct04441931) of ly-cov016 in healthy u.s. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.